Maxpar® Direct™ Immune Profiling Assay™

Immunotherapy has transformed cancer treatment but 60-70% of patients still fail to respond to these treatments. The challenge lies in accurately identifying which patients will benefit from these therapies due to inadequate predictive biomarkers. However, the solution to this extends far beyond simply identifying more biomarkers.

Addressing existing challenges requires integrated platforms that maintain analytical depth while providing the standardization, throughput, and regulatory compliance needed for clinical implementation. Standard Biotools has developed advanced immune profiling technologies that simultaneously capture functional states, rare cell populations, and spatial relationships to help identify predictive biomarkers for immunotherapy response.

Download this SelectScience guide to explore how to:

• Reveal hidden biomarkers via functional immune profiling
• Scale discovery to clinical reality
• Capture spatial context and dynamic range
• Integrate transcriptomics and proteomics

Resource details:

• Document type: SelectScience guide
• Page count: 40
• Read time: 60 mins
• Edition: 1st

Explore validation testing on the Maxpar Direct Immune Profiling Assay panel that confirms high reproducibility across multiple sites, high repeatability across sample types, including whole blood and PBMC, and robust intermediate precision when used by different technicians.

This technical note outlines why the high dynamic range of IMC technology is critical for protein quantification and enables the assessment of expression level without saturation of signals. It also outlines the significance of detecting low-level marker expression (highlighting PD-1, PD-L1 and CTLA-4); how IMC technology allows for clear analysis of low-abundance markers, and examples of PD-1, PD-L1 and CTLA-4 marker expression analysis using IMC systems.

In this flyer, Fluidigm demonstrates the capabilities of the Maxpar Direct Immune Profiling System and discusses how this system is designed as a simple single-tube workflow that brings together CyTOF technology, a day 30-marker antibody panel, and automated analysis with Maxpar Pathsetter software, so you can easily quantify 37 immune cell populations.

Immune profiling is the practice of identifying and quantifying immune populations according to their phenotypic and functional features. Performing immune profiling longitudinally, a process referred to as immune monitoring is an especially valuable technique to study conditions where the immune system plays a key role in the pathology, progression, or resolution of disease. In this white paper, Fluidigm introduces the Maxpar Direct Immune Profiling Assay, designed to provide a convenient and reliable solution for deep immune profiling.

The Maxpar® Direct™ Immune Profiling System has set a new standard for comprehensive immunophenotyping of human PBMC and whole blood by enabling simultaneous identification and enumeration of 37 immune subsets. This application note describes a proof-of-concept study where human whole blood samples stained with the Maxpar® Direct™ Immune Profiling Assay™ were cryopreserved for up to 120 days then thawed, data was acquired on a Helios mass cytometer and analyzed with Maxpar Pathsetter software.

In this poster, Fluidigm demonstrates the applications of both the Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter Analysis technologies.

Providing researchers with expanded capabilities in interrogating the tissue microenvironment

Watch this on-demand webinar to discover how mass cytometry can be used to monitor immune responses to new therapeutics

Study suggests that type I IFN deficiency in the blood could help define a high-risk population

Join this webinar to discover how cytometry can be used to monitor immune responses to new therapeutics and how the Maxpar Direct Immune Profiling System can help meet the demands of your COVID-19 research